- Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial
-
Inoue N, Kobayashi , Naganuma M, Hirai F, Ozawa M, Arikan D, Huang B, Robinson A, Thakkar RB, Hibi T
- KMID: 2382384
- Intest Res.
- 2017 Jul;15(3):395-401.
- doi: 10.5217/ir.2017.15.3.395
BACKGROUND/AIMS: Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through... -
- CITED
-
- Close
- SHARE
-
- Close
- Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
-
Wu KC, Ran ZH, Gao X, Chen M, Zhong J, Sheng JQ, Kamm MA, Travis S, Wallace K, Mostafa NM, Shapiro M, Li Y, Thakkar RB, Robinson A
- KMID: 2425288
- Intest Res.
- 2016 Apr;14(2):152-163.
- doi: 10.5217/ir.2016.14.2.152
BACKGROUND/AIMS: This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD). METHODS: Thirty, adult Chinese patients with CD... -
- CITED
-
- Close
- SHARE
-
- Close
